Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02392039 · ClinicalTrials.gov registry record · Early Phase 1
Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT02392039: Clinical Trial Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT02392039 is a Early Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02392039, a Early Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if loratadine can control bone pain caused by pegfilgrastim (a drug given after chemotherapy to help raise white blood cell counts).
Interventions
- OTHER Placebo
- BEHAVIORAL Questionnaires
- DRUG Pegfilgrastim
- DRUG Loratadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-12-14 |
| Est. Completion | 2018-04-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02392039
The ClinicalTrials.gov registry entry for NCT02392039 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02392039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02392039 about?
NCT02392039 is a clinical study titled "Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma". The goal of this clinical research study is to learn if loratadine can control bone pain caused by pegfilgrastim (a drug given after chemotherapy to help raise white blood cell counts).
What is the current status of trial NCT02392039?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2015-12-14. Estimated completion is 2018-04-04.
What interventions are being tested in trial NCT02392039?
The interventions under investigation include: Placebo (OTHER), Questionnaires (BEHAVIORAL), Pegfilgrastim (DRUG), Loratadine (DRUG).
Who is sponsoring clinical trial NCT02392039?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.